Jeffrey A. Breall, MD, PhD
Professor of Clinical Medicine
Dr. Breall received his undergraduate degree in physiology from the University of California at Berkeley and his PhD in physiology at the University of California at San Francisco, where he worked in the laboratory of Dr. Abraham M. Rudolph in the Cardiovascular Research Institute. Dr. Breall earned his MD degree at the Albert Einstein College of Medicine. He also spent several months in the coronary laboratory of Dr. Edward Kirk. Breall completed his residency and fellowship research training in cardiovascular diseases and interventional cardiology at Beth Israel Hospital and Harvard Medical School in Boston. Dr. Breall was on the faculty at Georgetown University for seven years where he served as Associate Director of the Cardiac Catheterization Laboratories and Interventional Cardiology. He came to Indiana University in 2000 to lead the interventional section. He has participated in numerous multi-center clinical trials, and has authored many papers and book chapters. Dr. Breall specializes in high-risk coronary intervention. He is the Director of the Cardiac Catheterization Laboratories and head of Interventional Cardiology for Indiana University and Medical Director of the Cardiac Catheterization Laboratories for Clarian Health Partners. He has had a long-standing interest in new devices and new pharmacologic agents for percutaneous coronary and cardiac intervention, as well as quality improvement in the catheterization laboratory. Breall is a member of the Councils on Clinical Cardiology Cardiovascular Radiology and Intervention and Fellow of the American Heart Association, the American College of Cardiology, American College of Chest Physicians, and American College of Physicians.
Krannert Institute of Cardiology 1800 N. Capitol Ave., Suite E-490
Indianapolis, IN 46202-1228
Titles & Appointments
- Clinical Information and Safety Officer
New devices and drugs for coronary intervention Percutaneous treatment of Hypertrophic Obstructive Cardiomyopathy Quality Assurance in the cardiac catheterization laboratory
Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention.
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.
A comparison of the use of traditional hand injection versus automated contrast injectors during cardiac catheterization.
Cardiac events after non-cardiac surgery in patients with previous coronary intervention in the drug-eluting stent era.
Successful use of the Impella device in giant cell myocarditis as a bridge to permanent left ventricular mechanical support.
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.
American Heart Association
American Board of Internal Medicine - Cardiology